Latest Articles

Publication Date
All News Scientific
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - Canada NewsWire

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer Canada NewsWire

Published: Dec. 5, 2024, 2:43 p.m.
Read Full Article
How to deal with anxiety after cancer treatment - The Australian Women's Weekly

How to deal with anxiety after cancer treatment The Australian Women's Weekly

Published: Dec. 4, 2024, 11:17 p.m.
Read Full Article
Endometriosis, fibroids and heavy periods: long-term research supports treatment decisions - NIHR Evidence

Endometriosis, fibroids and heavy periods: long-term research supports treatment decisions NIHR Evidence

Published: Dec. 4, 2024, 8 a.m.
Read Full Article
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast

Hutchmed endometrial cancer treatment gets conditional approval in China ShareCast

Published: Dec. 3, 2024, 10:28 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire

Published: Dec. 3, 2024, 10:01 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Canada Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Canada Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance UK

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance UK

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
Mental health, endometriosis treatment behind a spike in young people taking up private health insurance - ABC News

Mental health, endometriosis treatment behind a spike in young people taking up private health insurance ABC News

Published: Dec. 3, 2024, 2:26 a.m.
Read Full Article
Access To Endometriosis Treatment A “Significant And Welcome Change” - ELLE Australia

Access To Endometriosis Treatment A “Significant And Welcome Change” ELLE Australia

Published: Dec. 2, 2024, 11:09 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!